Medicalgorithmics enters a period of dynamic growth – Q2 revenues up 17.6% Year-over-Year, driven by a 136% increase in AI-based software sales in the U.S.
Medicalgorithmics, a Warsaw Stock Exchange-listed leader in cardiac diagnostic software, has published its preliminary revenue results for the second quarter of 2025. The Polish medtech company increased its revenues by 17.6% year-over-year. According to the Management Board, Medicalgorithmics is entering a phase of dynamic growth, fueled by record interest in its innovative AI-based software, which gained global recognition in the prestigious Nature Medicine journal. Since the beginning of 2025, Medicalgorithmics has signed 12 new client agreements, including two in the U.S. market. These new contracts are already contributing to Q2 results, and the company anticipates increased monetization of these agreements in the coming quarters.